glp 1 and biologics The World's First GCG/GLP-1 Dual Agonist The Therapeutic Potential of GLP-1

The pharmacokinetics of LY3437943 (retatrutide) support once-weekly administration due to an elimination half-life of approximately 6 days. Jastreboff AM et al., Nature Medicine, 2023 This extended half-life is made possible by attaching a fatty acid chain to the peptide, allowing it to bind to albumin a common protein in your blood that acts like a slow-release carrier

tirzepatide or retatrutide vs

Sip throughout the day to fight dry mouth and rinse away acids

Insurance coverage for GLP-1 agonist medication or incretin-based therapies for weight loss to provide effective long-term patient care takes precedence

But well talk a bit about some of the potential implications of that

Lancet 394(10193):121130